---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-016388"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2025-06-25T23:59:59+00:00"
generated_at: "2026-05-18T19:57:27.276326+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# ZyVersa enters $10M equity purchase agreement with Williamsburg Venture Holdings to fund VAR 200 clinical development

## Summary
- Up to $10M of common stock; company controls timing and amount of sales over 24-month term.
- Purchase price set at 94% of lowest VWAP during three trading days after each sale clears.
- 2.5% commitment fee in common shares, with piggyback registration rights; no warrants or derivatives.
- Funds intended to progress clinical development of Cholesterol Efflux Mediator TM VAR 200 for chronic kidney disease.
- Issuance capped at 19.99% of outstanding shares unless stockholder approval is obtained.

## SEC filing metadata
- accession: 0001641172-25-016388
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2025-06-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000164117225016388/0001641172-25-016388-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000164117225016388/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-016388
- JSON: https://secwatch.observer/filing/0001641172-25-016388.json
- Plain text: https://secwatch.observer/filing/0001641172-25-016388.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.